Clinical trials: Acute Myeloid Leukemia, Relapsed, Adult
AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- Conditions
- AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy
- Trial name
- NCT07014449
- Testing
- WBC100 QD
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Weben Pharma Co., Ltd
Relapsed Adult AML, Refractory AML
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
This is an open-label Phase I dose-escalation study of oral venetoclax in combination with increasing cytarabine doses plus mitoxantrone to define the safety profile and MTD of cytarabine in subjects with a histologically or…
- Trial name
- RELAX (NCT04330820)
- Testing
- Venetoclax Oral Tablet
- Where
- 12 sites in Germany
- Volunteers
- 55 people
- Sponsor
- Technische Universität Dresden
Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" [cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)] in the treatment of acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, Relapsed, Adult
- Trial name
- NCT04050280
- Testing
- Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Maryland, Baltimore
Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4)…
- Conditions
- Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
- Trial name
- BMT-13 (NCT06802315)
- Testing
- Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Illinois at Chicago
Relapsed Adult AML, Stem Cell Transplant Complications
Menin-Inhibitor Targeted Maintenance in AML
Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML.
- Conditions
- Relapsed Adult AML, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Transplant-Related Hematologic Malignancy
- Trial name
- NCT07563010
- Testing
- Revumenib
- Volunteers
- 146 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Relapsed Adult AML, Refractory AML
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy…
- Conditions
- Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia
- Trial name
- NCT07591649
- Testing
- AdaptNK, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Refractory Acute Leukemia
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This study is to investigate the therapeutic efficacy and side effect of chidamide, azacitidine combined with priming HAG regimen for relapsed or refractroy acute myeloid leukemia
- Conditions
- Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML
- Trial name
- NCT05029141
- Testing
- CAHAG regimen
- Where
- China
- Volunteers
- 21 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult
Natural Killer-cell Therapy for Acute Myeloid Leukemia
This study investigates an innovative treatment for relapsed or refractory acute myeloid leukemia exploiting administration of ex vivo-generated allogeneic natural killer (NK) cells with preceding non-myeloablative conditioning…
- Trial name
- NK4AML (NCT04347616)
- Testing
- UCB-NK cells, IL-2
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- Radboud University Medical Center
AML/MDS, CMML
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination with Azacitidine in Subjects with…
- Conditions
- AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04139434
- Testing
- LP-108, LP-108 and azacitidine
- Where
- 7 sites in United States, Spain
- Volunteers
- 32 people
- Sponsor
- Newave Pharmaceutical Inc
Relapsed Adult AML
Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19
Refractory/Relapsed (R/R) acute myeloid leukemia (AML) is associated with a dis-mal prognosis. In some subsets of AML such as AML driven by the t(8;21) translocation, leading to the RUNX1-RUNX1T1 (AML1-ETO) fusion transcript…
- Trial name
- CARLA-M19 (NCT06649227)
- Testing
- CAR-T cell therapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Lille
Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia
Novel Digital Application for Patients With Acute Leukemia
This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid…
- Conditions
- Relapsed Adult Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
- Trial name
- NAVIGATE (NCT06472128)
- Testing
- DREAMLAND, VITAL WELLNESS
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Massachusetts General Hospital
Relapsed Adult AML, Refractory AML
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
This study is a single-arm, open-label, dose-escalation clinical trial aimed at exploring the safety, tolerability, and pharmacokinetic characteristics of the CLL-1 CAR NK cells, as well as providing preliminary observations on…
- Trial name
- NCT06307054
- Testing
- anti-CLL-1 CAR NK cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
This is a phase I, dose-escalation, open-label clinical trial determining the safety and tolerability of adding Pitavastatin to Venetoclax in subjects with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML).
- Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult, CLL
- Trial name
- NCT04512105
- Testing
- Pitavastatin, Venetoclax
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Irvine
Leukemia, Myeloid, Acute, Relapsed Adult AML
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
- Conditions
- Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia
- Trial name
- NCT05305859
- Testing
- venetoclax combining chidamide and azacitidine (VCA)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Leukemia, Myeloid, Acute, Refractory AML
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with…
- Conditions
- Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2
- Trial name
- TUSCANY (NCT03850574)
- Testing
- Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 240 people
- Sponsor
- Aptose Biosciences Inc.
Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute…
- Conditions
- Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
- Trial name
- SCOPE-L (NCT05237258)
- Testing
- Specialty Palliative Care, Primary Palliative Care
- Where
- 20 sites in United States
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
AML, Adult, Refractory AML
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Approximately 30% of adult AML subjects are refractory to induction therapy. Furthermore, of those who achieve CR, approximately 75% will relapse. FLT3-mutated AML comprise an especially poor prognosis group.
- Conditions
- AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation
- Trial name
- OGILAR (NCT06022003)
- Testing
- AzaCITIDine Oral Tablet, Xospata
- Where
- 20 sites in France
- Volunteers
- 33 people
- Sponsor
- French Innovative Leukemia Organisation
Relapsed Adult AML
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.
- Trial name
- NCT06613217
- Testing
- zelenirstat
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Pacylex Pharmaceuticals
Relapsed/Refractory AML, AML, Adult
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory…
- Conditions
- Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
- Trial name
- NCT04623944
- Testing
- NKX101 - CAR NK cell therapy
- Where
- 8 sites in United States
- Volunteers
- 61 people
- Sponsor
- Nkarta, Inc.
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated